Cargando…
Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase
Necroptosis and signaling regulated by RIP1 kinase activity is emerging as a key driver of inflammation in a variety of disease settings. A significant amount has been learned about how RIP1 regulates necrotic cell death through the use of the RIP1 kinase inhibitor Necrostatin-1 (Nec-1). Nec-1 has b...
Autores principales: | Berger, SB, Harris, P, Nagilla, R, Kasparcova, V, Hoffman, S, Swift, B, Dare, L, Schaeffer, M, Capriotti, C, Ouellette, M, King, BW, Wisnoski, D, Cox, J, Reilly, M, Marquis, RW, Bertin, J, Gough, PJ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979471/ https://www.ncbi.nlm.nih.gov/pubmed/27551444 http://dx.doi.org/10.1038/cddiscovery.2015.9 |
Ejemplares similares
-
Life after death: RIP1 and RIP3 move beyond necroptosis
por: Berger, SB, et al.
Publicado: (2016) -
Identification of a RIP1 Kinase Inhibitor Clinical
Candidate (GSK3145095) for the Treatment of Pancreatic Cancer
por: Harris, Philip A., et al.
Publicado: (2019) -
Drilling into RIP1 biology: what compounds are in your toolkit?
por: Berger, S B, et al.
Publicado: (2015) -
OR3-001 – RIP2 kinase is activated in Blau Syndrome and IBD
por: Foley, KP, et al.
Publicado: (2013) -
963 Can telemedicine improve postpartum access to care?
por: Sagaram, Deepika, et al.
Publicado: (2021)